Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Leukemia 43Recurrence 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Non-Hodgkin 21Hematologic Neoplasms 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Leukemia, Myeloid 11Neoplasm, Residual 10Myeloproliferative Disorders 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Multiple Myeloma 9Lymphoma, Mantle-Cell 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Chromosome 17 deletion 6Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia, B-Cell 5Burkitt Lymphoma 5Primary Myelofibrosis 4GATA2 Deficiency 4Blast Crisis 4

Interventions

venetoclax 1obinutuzumab 1liposomal doxorubicin 1duvelisib 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1CA-4948 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × venetoclax × Other hematologic neoplasm × Clear all
NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Curis, Inc.

Phase 1/2 Suspended
366 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡